BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:29 PM
Oct 01, 2012
 |  BC Extra  |  Clinical News

Lilly reports Phase II NSCLC data for ramucirumab

Eli Lilly and Co. (NYSE:LLY) reported data from a pair of open-label Phase II trials of ramucirumab to treat advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology meeting in Vienna. In 140 evaluable chemotherapy-naïve patients with advanced non-squamous NSCLC,...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >